Objective: To determine the dose of coenzyme Q (CoQ) needed to achieve at least a 3-fold increase in plasma CoQ concentration in dogs with myxomatous mitral valve disease (MMVD) and congestive heart failure (CHF).
Animals: 18 dogs with CHF due to MMVD and 12 healthy dogs.
Procedures: In a randomized, double-blinded, controlled trial, dogs with MMVD were given 50 or 100 mg of water-soluble CoQ (ubiquinone; total daily dose, 100 mg [n = 5] or 200 mg [6]) or a placebo (7), PO, twice a day for 2 weeks in addition to regular cardiac treatment. Plasma CoQ concentration was measured in dogs with MMVD before (baseline) and at various time points after supplementation began and in healthy dogs once. Concentrations were compared among and within groups.
Results: No significant difference in median baseline plasma CoQ concentration was detected between healthy dogs and dogs with MMVD. Fold increases in plasma CoQ concentrations ranged from 1.7 to 4.7 and 3.2 to 6.8 for individual dogs in the 100-mg and 200-mg groups, respectively. The change in plasma CoQ concentration after supplementation began was significantly higher than in the placebo group at 4 hours and 1 and 2 weeks for dogs in the 200-mg group and at 1 and 2 weeks for dogs in the 100-mg group.
Conclusions And Clinical Relevance: A daily CoQ dose of 200 mg was sufficient to achieve at least a 3-fold increase in plasma CoQ concentration and may be used in CoQ supplementation studies involving dogs with CHF due to MMVD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2460/ajvr.82.4.280 | DOI Listing |
Antioxidants (Basel)
December 2024
Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
The prolonged consumption of D-galactose (Gal) has been associated with severe damage in the liver and brain via exacerbation of oxidative stress, non-enzymatic glycation, and the aging process. The current study was initiated for a comparative assessment of beeswax alcohol (BWA, final 0.5% and 1.
View Article and Find Full Text PDFPharmaceuticals (Basel)
September 2024
Raydel Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea.
The current study was designed to compare in vivo efficacy between beeswax alcohol (BWA) and coenzyme Q (CoQ) to treat fatty liver changes, oxidative stress, and damages in major organs of zebrafish by 12 weeks with high-cholesterol (HC) and galactose (Gal) supplementation. At week 12, the HC control and HC+Gal control groups showed 96% and 92% survivability, respectively, while co-supplementation of the 0.5% BWA and 1.
View Article and Find Full Text PDFCell Death Dis
September 2024
Graduate School of Environmental Sciences, Hokkaido University, Sapporo, Japan.
Nat Commun
September 2024
Laboratory of Angiogenesis and Cancer Metabolism, Department of Biology, University of Padova, Padova, Italy.
CoQ (Coenzyme Q) is an essential fat-soluble metabolite that plays a key role in cellular metabolism. A less-known function of CoQ is whether it may act as a plasma membrane-stabilizing agent and whether this property can affect cancer development and progression. Here, we show that CoQ and its biosynthetic enzyme UBIAD1 play a critical role in plasmamembrane mechanical properties that are of interest for breast cancer (BC) progression and treatment.
View Article and Find Full Text PDFAntioxidants (Basel)
August 2024
Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain.
Coenzyme Q10 (CoQ) is a ubiquitous lipid with different biological functions. In blood, there is a close relationship between CoQ status and cholesterol, which strongly supports the study of both molecules simultaneously. The objective of this study was to evaluate plasma CoQ, lipoprotein concentrations and CoQ/Chol ratio in a cohort of paediatric patients with different types of dyslipidaemias.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!